Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 PATENT ANALYSIS
5.4 TECHNOLOGICAL ADVANCEMENT IN THERAPY
5.5 REIMBURSEMENT SCENARIO
5.6 SYNOVIAL SARCOMA TREATMENT MARKET ANALYSIS (QUALITATIVE AND QUANTITATIVE ANALYSIS)
6 EPIDEMIOLOGY
6.1 PREVALENCE RATE OF SOFT TISSUE SARCOMA
6.2 INCIDENCE RATE OF SOFT TISSUE SARCOMA
6.3 DIAGNOSIS AND TREATMENT RATE OF SOFT TISSUE SARCOMA
6.4 MORTALITY RATE OF SOFT TISSUE SARCOMA
7 INDUSTRY INSIGHTS
7.1 KEY PRICING STRATEGIES
7.2 INTERVIEWS WITH STERILIZATION COMPANIES
7.3 INTERVIEWS WITH SERVICE PROVIDERS
7.4 INTERVIEWS WITH RESEARCH SCHOLARS
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMEWORK
9 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, BY DIAGNOSIS AND TREATMENT TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 IMAGING
9.2.1.1. MAGNETIC RESONANCE IMAGING
9.2.1.2. COMPUTED TOMOGRAPHY
9.2.1.3. OTHERS
9.2.2 BIOPSY
9.2.3 OTHERS
9.3 TREATMENT
9.3.1 MEDICATION
9.3.1.1. MEDICATION, BY COMMERCIALIZATION
9.3.1.1.1. MEDICATION, BY MARKETED PRODUCTS
9.3.1.1.1.1 DOXORUBICIN
9.3.1.1.1.2 IFOSFAMIDE
9.3.1.1.1.3 OTHERS
9.3.1.1.2. MEDICATION, BY PIPELINE PRODUCTS
9.3.1.1.2.1 TBI-1301
9.3.1.1.2.2 FHD-609
9.3.1.1.2.3 OTSA101-DTPA
9.3.1.1.2.4 CFT8634
9.3.1.1.2.5 ADP-A2M4
9.3.1.1.2.6 AL3818
9.3.1.1.2.7 AFAMITRESGENE AUTOLEUCEL
9.3.1.1.2.8 TP-1287
9.3.1.1.2.9 ITACITINIB
9.3.1.1.2.10 CAB-AXL-ADC
9.3.1.1.2.11 TAZEMETOSTAT
9.3.1.1.2.12 MAGE-A4C1032T
9.3.1.1.2.13 NANOPLEXED POLY I:C BO-112
9.3.1.1.2.14 OTHERS
9.3.1.2. MEDICATION, BY NATURE OF PRODUCT
9.3.1.2.1. BIOLOGICAL
9.3.1.2.1.1 NY-ESO-1(C259) T CELLS
9.3.1.2.1.2 ANTI-NY-ESO-1
9.3.1.2.1.3 TCR-TRANSDUCED T CELL
9.3.1.2.1.4 TBI-1301
9.3.1.2.1.5 AUTOLOGOUS DENDRITIC CELL VACCINE
9.3.1.2.1.6 TELOMERASE VACCINE
9.3.1.2.1.7 OTHERS
9.3.1.2.2. NON-BIOLOGICAL
9.3.2 SURGERY
9.3.3 RADIATION THERAPY
10 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 PEDIATRIC
10.3 ADULTS
10.4 GERIATRIC
11 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, BY STAGE
11.1 OVERVIEW
11.2 STAGE 1
11.3 STAGE 2
11.4 STAGE 3
11.5 STAGE 4
12 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 RADIATION CENTERS
12.5 ACADEMIC AND RESEARCH INSTITUTES
12.6 OTHERS
13 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, BY GEOGRAPHY
14.1 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1.1 NORTH AMERICA
14.1.1.1. U.S.
14.1.1.1.1. U.S SYNOVIAL SARCOMA TREATMENT MARKET, BY DIAGNOSIS AND TREATMENT TYPE
14.1.1.1.2. U.S SYNOVIAL SARCOMA TREATMENT MARKET, BY AGE GROUP
14.1.1.1.3. U.S SYNOVIAL SARCOMA TREATMENT MARKET BY STAGE
14.1.1.1.4. U.S SYNOVIAL SARCOMA TREATMENT MARKET BY END USER
14.1.1.1.5. U.S SYNOVIAL SARCOMA TREATMENT MARKET BY DISTRIBUTION CHANNEL
14.1.1.2. CANADA
14.1.1.3. MEXICO
14.1.2 EUROPE
14.1.2.1. GERMANY
14.1.2.2. FRANCE
14.1.2.3. U.K.
14.1.2.4. ITALY
14.1.2.5. SPAIN
14.1.2.6. RUSSIA
14.1.2.7. TURKEY
14.1.2.8. BELGIUM
14.1.2.9. NETHERLANDS
14.1.2.10. SWITZERLAND
14.1.2.11. REST OF EUROPE
14.1.3 ASIA-PACIFIC
14.1.3.1. JAPAN
14.1.3.2. CHINA
14.1.3.3. SOUTH KOREA
14.1.3.4. INDIA
14.1.3.5. AUSTRALIA
14.1.3.6. SINGAPORE
14.1.3.7. THAILAND
14.1.3.8. MALAYSIA
14.1.3.9. INDONESIA
14.1.3.10. PHILIPPINES
14.1.3.11. REST OF ASIA-PACIFIC
14.1.4 SOUTH AMERICA
14.1.4.1. BRAZIL
14.1.4.2. ARGENTINA
14.1.4.3. PERU
14.1.4.4. CHILE
14.1.4.5. COLOMBIA
14.1.4.6. VENEZUELA
14.1.4.7. REST OF SOUTH AMERICA
14.1.5 MIDDLE EAST AND AFRICA
14.1.5.1. SOUTH AFRICA
14.1.5.2. SAUDI ARABIA
14.1.5.3. UAE
14.1.5.4. EGYPT
14.1.5.5. ISRAEL
14.1.5.6. REST OF MIDDLE EAST AND AFRICA
14.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL SYNOVIAL SARCOMA TREATMENT MARKET, COMPANY PROFILE
17.1 ADAPTIMMUNE THERAPEUTICS PLC
17.1.1 COMPANY OVERVIEW
17.1.2 REVENUE ANALYSIS
17.1.3 GEOGRAPHIC PRESENCE
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPEMENTS
17.2 GSK PLC.
17.2.1 COMPANY OVERVIEW
17.2.2 REVENUE ANALYSIS
17.2.3 GEOGRAPHIC PRESENCE
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPEMENTS
17.3 ELI LILLY AND COMPANY
17.3.1 COMPANY OVERVIEW
17.3.2 REVENUE ANALYSIS
17.3.3 GEOGRAPHIC PRESENCE
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPEMENTS
17.4 FOGHORN THERAPEUTICS.
17.4.1 COMPANY OVERVIEW
17.4.2 REVENUE ANALYSIS
17.4.3 GEOGRAPHIC PRESENCE
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPEMENTS
17.5 ADVENCHEN LABORATORIES, LLC
17.5.1 COMPANY OVERVIEW
17.5.2 REVENUE ANALYSIS
17.5.3 GEOGRAPHIC PRESENCE
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPEMENTS
17.6 SALARIUS PHARMACEUTICALS, INC.
17.6.1 COMPANY OVERVIEW
17.6.2 REVENUE ANALYSIS
17.6.3 GEOGRAPHIC PRESENCE
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPEMENTS
17.7 C4 THERAPEUTICS, INC.
17.7.1 COMPANY OVERVIEW
17.7.2 REVENUE ANALYSIS
17.7.3 GEOGRAPHIC PRESENCE
17.7.4 PRODUCT PORTFOLIO
17.7.5 RECENT DEVELOPEMENTS
17.8 OTSUKA PHARMACEUTICAL CO., LTD.
17.8.1 COMPANY OVERVIEW
17.8.2 REVENUE ANALYSIS
17.8.3 GEOGRAPHIC PRESENCE
17.8.4 PRODUCT PORTFOLIO
17.8.5 RECENT DEVELOPEMENTS
17.9 IMMUNOCORE, LTD.
17.9.1 COMPANY OVERVIEW
17.9.2 REVENUE ANALYSIS
17.9.3 GEOGRAPHIC PRESENCE
17.9.4 PRODUCT PORTFOLIO
17.9.5 RECENT DEVELOPEMENTS
17.1 SUMITOMO PHARMA ONCOLOGY, INC.
17.10.1 COMPANY OVERVIEW
17.10.2 REVENUE ANALYSIS
17.10.3 GEOGRAPHIC PRESENCE
17.10.4 PRODUCT PORTFOLIO
17.10.5 RECENT DEVELOPEMENTS
17.11 TAKARA BIO INC.
17.11.1 COMPANY OVERVIEW
17.11.2 REVENUE ANALYSIS
17.11.3 GEOGRAPHIC PRESENCE
17.11.4 PRODUCT PORTFOLIO
17.11.5 RECENT DEVELOPEMENTS
17.12 PHARMAMAR
17.12.1 COMPANY OVERVIEW
17.12.2 REVENUE ANALYSIS
17.12.3 GEOGRAPHIC PRESENCE
17.12.4 PRODUCT PORTFOLIO
17.12.5 RECENT DEVELOPEMENTS
17.13 BAYER AG
17.13.1 COMPANY OVERVIEW
17.13.2 REVENUE ANALYSIS
17.13.3 GEOGRAPHIC PRESENCE
17.13.4 PRODUCT PORTFOLIO
17.13.5 RECENT DEVELOPEMENTS
17.14 GE HEALTHCARE.
17.14.1 COMPANY OVERVIEW
17.14.2 REVENUE ANALYSIS
17.14.3 GEOGRAPHIC PRESENCE
17.14.4 PRODUCT PORTFOLIO
17.14.5 RECENT DEVELOPEMENTS
17.15 KONINKLIJKE PHILIPS N.V.
17.15.1 COMPANY OVERVIEW
17.15.2 REVENUE ANALYSIS
17.15.3 GEOGRAPHIC PRESENCE
17.15.4 PRODUCT PORTFOLIO
17.15.5 RECENT DEVELOPEMENTS
17.16 SIEMENS HEALTHCARE
17.16.1 COMPANY OVERVIEW
17.16.2 REVENUE ANALYSIS
17.16.3 GEOGRAPHIC PRESENCE
17.16.4 PRODUCT PORTFOLIO
17.16.5 RECENT DEVELOPEMENTS
17.17 PERKINELMER INC.
17.17.1 COMPANY OVERVIEW
17.17.2 REVENUE ANALYSIS
17.17.3 GEOGRAPHIC PRESENCE
17.17.4 PRODUCT PORTFOLIO
17.17.5 RECENT DEVELOPEMENTS
17.18 FUJIFILM
17.18.1 COMPANY OVERVIEW
17.18.2 REVENUE ANALYSIS
17.18.3 GEOGRAPHIC PRESENCE
17.18.4 PRODUCT PORTFOLIO
17.18.5 RECENT DEVELOPEMENTS
17.19 BD
17.19.1 COMPANY OVERVIEW
17.19.2 REVENUE ANALYSIS
17.19.3 GEOGRAPHIC PRESENCE
17.19.4 PRODUCT PORTFOLIO
17.19.5 RECENT DEVELOPMENTS
17.2 IZI MEDICAL PRODUCTS
17.20.1 COMPANY OVERVIEW
17.20.2 REVENUE ANALYSIS
17.20.3 GEOGRAPHIC PRESENCE
17.20.4 PRODUCT PORTFOLIO
17.20.5 RECENT DEVELOPMENTS
17.21 MEDAX
17.21.1 COMPANY OVERVIEW
17.21.2 REVENUE ANALYSIS
17.21.3 GEOGRAPHIC PRESENCE
17.21.4 PRODUCT PORTFOLIO
17.21.5 RECENT DEVELOPMENTS
17.22 TERUMO CORPORATION
17.22.1 COMPANY OVERVIEW
17.22.2 REVENUE ANALYSIS
17.22.3 GEOGRAPHIC PRESENCE
17.22.4 PRODUCT PORTFOLIO
17.22.5 RECENT DEVELOPMENTS
17.23 INRAD, INC.
17.23.1 COMPANY OVERVIEW
17.23.2 REVENUE ANALYSIS
17.23.3 GEOGRAPHIC PRESENCE
17.23.4 PRODUCT PORTFOLIO
17.23.5 RECENT DEVELOPMENTS
17.24 MEDICAL SYSTEMS.
17.24.1 COMPANY OVERVIEW
17.24.2 REVENUE ANALYSIS
17.24.3 GEOGRAPHIC PRESENCE
17.24.4 PRODUCT PORTFOLIO
17.24.5 RECENT DEVELOPMENTS
17.25 REMINGTON MEDICAL INC.
17.25.1 COMPANY OVERVIEW
17.25.2 REVENUE ANALYSIS
17.25.3 GEOGRAPHIC PRESENCE
17.25.4 PRODUCT PORTFOLIO
17.25.5 RECENT DEVELOPMENTS
17.26 MEDIGENE
17.26.1 COMPANY OVERVIEW
17.26.2 REVENUE ANALYSIS
17.26.3 GEOGRAPHIC PRESENCE
17.26.4 PRODUCT PORTFOLIO
17.26.5 RECENT DEVELOPMENTS
17.27 POINT BIOPHARMA
17.27.1 COMPANY OVERVIEW
17.27.2 REVENUE ANALYSIS
17.27.3 GEOGRAPHIC PRESENCE
17.27.4 PRODUCT PORTFOLIO
17.27.5 RECENT DEVELOPMENTS
17.28 TRACON PHARMA
17.28.1 COMPANY OVERVIEW
17.28.2 REVENUE ANALYSIS
17.28.3 GEOGRAPHIC PRESENCE
17.28.4 PRODUCT PORTFOLIO
17.28.5 RECENT DEVELOPMENTS
17.29 XIANGXUE LIFE SCIENCES
17.29.1 COMPANY OVERVIEW
17.29.2 REVENUE ANALYSIS
17.29.3 GEOGRAPHIC PRESENCE
17.29.4 PRODUCT PORTFOLIO
17.29.5 RECENT DEVELOPMENTS
18 CONCLUSION
19 QUESTIONNAIRE
20 ABOUT DATA BRIDGE MARKET RESEARCH
